MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Treatment Line Code System

Raw xml | Download

<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="treatment-line-cs"/>
  <language value="en"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem treatment-line-cs</b></p><a name="treatment-line-cs"> </a><a name="hctreatment-line-cs"> </a><p>This case-sensitive code system <code>http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style="white-space:nowrap">1L<a name="treatment-line-cs-1L"> </a></td><td>First-line</td><td>The first line of systemic anti-cancer therapy for this indication.</td></tr><tr><td style="white-space:nowrap">2L<a name="treatment-line-cs-2L"> </a></td><td>Second-line</td><td>The second line of systemic anti-cancer therapy; administered after first-line therapy failure, progression, or intolerance.</td></tr><tr><td style="white-space:nowrap">3L-plus<a name="treatment-line-cs-3L-plus"> </a></td><td>Third-line or later</td><td>The third or any subsequent line of systemic anti-cancer therapy.</td></tr><tr><td style="white-space:nowrap">maintenance<a name="treatment-line-cs-maintenance"> </a></td><td>Maintenance</td><td>Maintenance therapy administered to prolong response after induction or consolidation treatment.</td></tr></table></div>
  </text>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
    <valueCode value="cic"/>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status">
    <valueCode value="informative">
      <extension
                 url="http://hl7.org/fhir/StructureDefinition/structuredefinition-conformance-derivedFrom">
        <valueCanonical
                        value="http://hl7.org/fhir/us/codex-mopa/ImplementationGuide/hl7.fhir.us.codex-mopa"/>
      </extension>
    </valueCode>
  </extension>
  <url
       value="http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs"/>
  <version value="0.1.1-snapshot-080926"/>
  <name value="TreatmentLineCS"/>
  <title value="Treatment Line Code System"/>
  <status value="draft"/>
  <experimental value="true"/>
  <date value="2026-09-08T18:17:28-04:00"/>
  <publisher value="HL7 International / Clinical Interoperability Council"/>
  <contact>
    <name value="HL7 International / Clinical Interoperability Council"/>
    <telecom>
      <system value="url"/>
      <value value="http://www.hl7.org/Special/committees/cic"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="ciclist@lists.HL7.org"/>
    </telecom>
  </contact>
  <description
               value="Ordinal codes representing the line of systemic anti-cancer therapy.
These codes are used in TreatmentLineVS and in the LineOfTherapyRequestCategory constraint
profile for the RequestGroup `lineOfTherapy` category slice.

**mCODE Migration Candidate** — These codes are proposed for adoption in mCODE STU5
or as a SNOMED CT extension request. Once standard codes are available, this code
system should be deprecated."/>
  <jurisdiction>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <code value="US"/>
      <display value="United States of America"/>
    </coding>
  </jurisdiction>
  <purpose
           value="mCODE Migration Candidate — proposed for adoption in mCODE STU5 or as a SNOMED CT
extension request. Once standard codes are available this code system will be deprecated.
It is NOT intended to be a permanent artifact of this IG. See the mCODE Gap Proposals page
for the migration plan."/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="4"/>
  <concept>
    <code value="1L"/>
    <display value="First-line"/>
    <definition
                value="The first line of systemic anti-cancer therapy for this indication."/>
  </concept>
  <concept>
    <code value="2L"/>
    <display value="Second-line"/>
    <definition
                value="The second line of systemic anti-cancer therapy; administered after first-line therapy failure, progression, or intolerance."/>
  </concept>
  <concept>
    <code value="3L-plus"/>
    <display value="Third-line or later"/>
    <definition
                value="The third or any subsequent line of systemic anti-cancer therapy."/>
  </concept>
  <concept>
    <code value="maintenance"/>
    <display value="Maintenance"/>
    <definition
                value="Maintenance therapy administered to prolong response after induction or consolidation treatment."/>
  </concept>
</CodeSystem>